相关实验视频
Updated: Jan 9, 2026
03:52
The Creation of a Rat Model for Osteosarcopenia via Ovariectomy
Published on: February 21, 2025
1.0K
萨尔科佩尼亚及其组成部分对心力衰竭患者的影响:系统性审查和网络元分析
Trang Thi Quynh Tran1,2, Shih-Wei Huang3,4, Hung Quang Ho1,5
1International Ph.D. Program in Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Medicine
|December 2, 2025
概括
短物理性能电池 (SPPB) 最好预测心力衰竭 (HF) 患者的不良结果. 早期识别SPPB可以改善预后,并指导针对HF和肉类的向干预.
科学领域:
- 老年学和老年医学是老年学和老年医学.
- 心脏病学和心血管疾病.
- 肌肉骨健康 肌肉骨健康
背景情况:
- 在老年人中,心力衰竭 (HF) 和麻症经常并存,显著增加死亡率,住院和功能衰退.
- 在HF中准确评估肉类是具有挑战性的,因为在流体过载患者中,症状与虚弱和诊断困难重叠.
- 识别预测HF预后的特定肉类的成分对于有效的管理至关重要.
研究的目的:
- 确定哪些与肉类相关的成分是心力衰竭患者不良结果最强的预测因素.
- 为了澄清肌肉质量,力量和身体表现的不同测量方法的预后价值,在HF.
主要方法:
- 对观察纵向队列研究 (发表至2024年3月) 进行了系统性审查和频率网络元分析.
- 在PubMed,Web of Science,Embase和Scopus数据库中进行了搜索.
- 证据的确定性使用网络元分析的信心进行了评估;采用了元回归和灵敏度分析.
主要成果:
- 对43项研究 (38,768名高压患者) 的分析显示,短物理性能电池 (SPPB) 是不良预后的最强预测因素 (HR: 30.22).
- 其他预测因素包括萨尔科佩尼亚诊断 (HR:9.33),肌肉力量低 (HR:5.45),步行速度低 (HR:4.01),肌肉质量低 (HR:3.68).
- 发现了显著的异质性,敏感性分析表明,SPPB的极端危险比率受到特定切线的影响;整体证据确定性低至非常低.
结论:
- 短物理性能电池 (SPPB) 似乎是心力衰竭患者不良预后的关键指标.
- 这些发现表明,潜在需要针对性干预,重点关注SPPB组件.
- 需要进一步进行高质量的研究,使用标准化的评估来证实这些结果.
相关概念视频
01:17Pathophysiology of Heart Failure
2.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.7K
01:27Heart Failure I: Introduction
670
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
670
01:29Heart Failure II: Pathophysiology
685
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
685
01:30Heart Failure VII: Nursing Interventions
397
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
397
01:30Heart Failure V: Medical Management
200
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
200
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
888
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
888